Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sohye Kang

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Cancer Cell|May 16, 2006
Kinase inhibitors: vice becomes virtuePeter K Vogt, Sohye Kang
Virology|December 21, 2005
Phosphoinositide 3-kinase: from viral oncoprotein to drug targetPeter K Vogt, Andreas G Bader, Sohye Kang
Cell Cycle (Georgetown, Tex.)|May 12, 2006
PI 3-kinases: hidden potentials revealedPeter K Vogt, Andreas G Bader, Sohye Kang
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2006
Cancer-specific mutations in PIK3CA are oncogenic in vivoAndreas G Bader, Sohye Kang, Peter K Vogt
Proceedings of the National Academy of Sciences of the United States of America|January 14, 2005
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenicSohye Kang, Andreas G Bader, Peter K Vogt
Biotechnology and Bioengineering|March 27, 2012
Utilization of tyrosine- and histidine-containing dipeptides to enhance productivity and culture viabilitySohye Kang, Johanna Mullen, Les P Miranda, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2006
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinaseSohye Kang, Adam Denley, Bart Vanhaesebroeck, et al.
Nature Reviews. Cancer|December 13, 2005
Oncogenic PI3K deregulates transcription and translationAndreas G Bader, Sohye Kang, Li Zhao, et al.
Trends in Biochemical Sciences|June 15, 2007
Cancer-specific mutations in phosphatidylinositol 3-kinasePeter K Vogt, Sohye Kang, Marc-André Elsliger, et al.
Cell Cycle (Georgetown, Tex.)|May 7, 2005
Mutated PI 3-kinases: cancer targets on a silver platterSohye Kang, Andreas G Bader, Li Zhao, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Cancer Cell|May 16, 2006
Kinase inhibitors: vice becomes virtuePeter K Vogt, Sohye Kang
Virology|December 21, 2005
Phosphoinositide 3-kinase: from viral oncoprotein to drug targetPeter K Vogt, Andreas G Bader, Sohye Kang
Cell Cycle (Georgetown, Tex.)|May 12, 2006
PI 3-kinases: hidden potentials revealedPeter K Vogt, Andreas G Bader, Sohye Kang
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2006
Cancer-specific mutations in PIK3CA are oncogenic in vivoAndreas G Bader, Sohye Kang, Peter K Vogt
Proceedings of the National Academy of Sciences of the United States of America|January 14, 2005
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenicSohye Kang, Andreas G Bader, Peter K Vogt
Biotechnology and Bioengineering|March 27, 2012
Utilization of tyrosine- and histidine-containing dipeptides to enhance productivity and culture viabilitySohye Kang, Johanna Mullen, Les P Miranda, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2006
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinaseSohye Kang, Adam Denley, Bart Vanhaesebroeck, et al.
Nature Reviews. Cancer|December 13, 2005
Oncogenic PI3K deregulates transcription and translationAndreas G Bader, Sohye Kang, Li Zhao, et al.
Trends in Biochemical Sciences|June 15, 2007
Cancer-specific mutations in phosphatidylinositol 3-kinasePeter K Vogt, Sohye Kang, Marc-André Elsliger, et al.
Cell Cycle (Georgetown, Tex.)|May 7, 2005
Mutated PI 3-kinases: cancer targets on a silver platterSohye Kang, Andreas G Bader, Li Zhao, et al.
Pageof 2